Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
Date
2005
Authors
Kris, M.G.
Hesketh, P.J.
Herrstedt, J.
Rittenberg, C.
Einhorn, L.H.
Grunberg, S.
Koeller, J.
Olver, I.
Borjeson, S.
Ballatori, E.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Supportive Care in Cancer, 2005; 13(2):85-96
Statement of Responsibility
Mark G. Kris, Paul J. Hesketh, Jorn Herrstedt, Cynthia Rittenberg, Lawrence H. Einhorn, Steven Grunberg, Jim Koeller, Ian Olver, Sussanne Borjeson, Enzo Ballatori
Conference Name
Abstract
This paper uses an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents. We address issues of dose, schedule, and route of administration of five selective 5-HT3 antagonists. We conclude that for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration, even with chemotherapy of high emetic risk. Selective antagonists of the type 3 serotonin receptor (5-HT3) in combination with dexamethasone and aprepitant are the standard of care for the prevention of emesis following chemotherapy of high emetic risk.
School/Discipline
Dissertation Note
Provenance
Description
Published online: 23 November 2004.
Corrected by Erratum: Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy, in Support Care Cancer (2005) 13: 562. doi:10.1007/s00520-005-0833-4. In Table 1 the dosage of dolasetron was incorrectly given as 0.18 mg/kg. The correct dosage is 1.8 mg/kg.
Access Status
Rights
© Springer-Verlag 2004